Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 6 | 2015 | 46 | 1.090 |
Why?
|
| Cyclosporine | 1 | 2012 | 17 | 0.420 |
Why?
|
| Colectomy | 1 | 2012 | 23 | 0.420 |
Why?
|
| Gastrointestinal Agents | 1 | 2012 | 14 | 0.420 |
Why?
|
| Colitis | 1 | 2012 | 41 | 0.410 |
Why?
|
| Biological Products | 2 | 2015 | 46 | 0.360 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2007 | 9 | 0.350 |
Why?
|
| Anemia | 1 | 2007 | 100 | 0.250 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 59 | 0.250 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 2 | 0.250 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2005 | 2 | 0.250 |
Why?
|
| Hemochromatosis | 1 | 2005 | 3 | 0.250 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2014 | 89 | 0.210 |
Why?
|
| Colitis, Ulcerative | 3 | 2013 | 71 | 0.200 |
Why?
|
| Pouchitis | 3 | 2009 | 5 | 0.160 |
Why?
|
| Lymphoid Tissue | 1 | 2018 | 21 | 0.160 |
Why?
|
| Integrins | 1 | 2018 | 21 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 60 | 0.150 |
Why?
|
| Colonic Pouches | 2 | 2009 | 5 | 0.150 |
Why?
|
| Female | 11 | 2018 | 16980 | 0.140 |
Why?
|
| Male | 10 | 2018 | 16442 | 0.130 |
Why?
|
| Placenta | 1 | 2015 | 14 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Videoconferencing | 1 | 2014 | 3 | 0.120 |
Why?
|
| Education, Distance | 1 | 2014 | 20 | 0.120 |
Why?
|
| Humans | 13 | 2018 | 30994 | 0.120 |
Why?
|
| Erythema Nodosum | 1 | 2014 | 2 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 138 | 0.120 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2014 | 6 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 44 | 0.120 |
Why?
|
| Antibodies, Antinuclear | 1 | 2014 | 21 | 0.110 |
Why?
|
| DNA | 1 | 2014 | 124 | 0.110 |
Why?
|
| Middle Aged | 8 | 2018 | 10192 | 0.110 |
Why?
|
| Adult | 9 | 2018 | 8929 | 0.110 |
Why?
|
| Quality of Life | 3 | 2015 | 697 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 135 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1921 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 115 | 0.100 |
Why?
|
| HIV Infections | 1 | 2018 | 890 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2007 | 1898 | 0.090 |
Why?
|
| Biomarkers | 1 | 2014 | 733 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 499 | 0.090 |
Why?
|
| Depression | 1 | 2013 | 481 | 0.080 |
Why?
|
| Adolescent | 3 | 2015 | 2401 | 0.080 |
Why?
|
| Bone Density | 1 | 2009 | 152 | 0.070 |
Why?
|
| Tinidazole | 1 | 2007 | 1 | 0.070 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 28 | 0.070 |
Why?
|
| Ohio | 1 | 2007 | 9 | 0.070 |
Why?
|
| Prognosis | 3 | 2015 | 918 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 143 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 63 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 147 | 0.070 |
Why?
|
| Certolizumab Pegol | 1 | 2006 | 2 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2006 | 3 | 0.070 |
Why?
|
| Risk Factors | 3 | 2009 | 2586 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 114 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 225 | 0.060 |
Why?
|
| Prevalence | 1 | 2007 | 499 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 442 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2006 | 718 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2007 | 3806 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2018 | 11 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 30 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 89 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 95 | 0.040 |
Why?
|
| Young Adult | 2 | 2015 | 2063 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2018 | 329 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 226 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 20 | 0.030 |
Why?
|
| Jejunal Neoplasms | 1 | 2015 | 2 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 49 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 42 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 105 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 75 | 0.030 |
Why?
|
| Pregnancy | 1 | 2015 | 404 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 135 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 685 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 206 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 169 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 291 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 429 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 356 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 662 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 376 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1009 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 63 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 83 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1210 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2009 | 85 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 18 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 139 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 246 | 0.020 |
Why?
|
| Sex Factors | 1 | 2006 | 511 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2007 | 532 | 0.020 |
Why?
|
| Calcium | 1 | 2009 | 502 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 873 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 10045 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2042 | 0.010 |
Why?
|